Luminescent Cell Viability Testing
Employ INDIGO Biosciences’ Luminescent Cell Viability Testing Services for a powerful tool in assessing cell health and facilitating effective drug discovery and toxicity studies.
Validate Your Antagonist-Mode Data
The LCM assay allows users to validate their primary reporter assay data by determining if their test compound treatments exert mitogenic, cytostatic or cytotoxic activities on the reporter cells. The occurrence of such adverse non-specific effects will always undermine the accurate assessment of a test compound’s potency and/or efficacy as a modulator of receptor function.
When screening test compounds for antagonist activities (or inverse-agonist) it is particularly important to quantify changes in the relative number of live reporter cells at the assay endpoint. Test compounds that exert cytostatic, cytotoxic, or cytolytic activities invariably generate “false-positive” results in an antagonist screen. In such cases, the observed drop in luciferase activity will be incorrectly attributed to inhibition of the nuclear receptor by the test compound. In reality, however, the treatment compound has pushed the reporter cells into division arrest, apoptosis, necrosis, or lysis.
It is important to run this assay in multiplex when designing a study that looks at antagonist or inverse-agonist activities.
Get Started in Three Simple Steps
Design your next study rapidly and confidently with our expert team.
Step 2: Design Your Custom Assay with Our Scientists
Meet with our team and discuss the assay design you need and if we can help.
Receive your custom quote.
Step 3: Run Your Samples and Get Your Results
After the new assay is developed, order your new assay kits to perform in your lab, or have our scientists run the assay for you!